课题基金 / 基金详情

UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer

UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer
加州大学旧金山分校合成免疫学中心:重新编程免疫系统以对抗癌症的工具
批准号:
10598367
负责人:
WENDELL A LIM
金额:
$5.93万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-24 至 2024-08-31

项目摘要

项目成果

WENDELL A LIM的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer The immune system has emerged as an extraordinarily powerful tool for combating cancer. One of the most potent agents are engineered T cells programmed to recognize and kill tumor cells. Nonetheless, our ability to engineer T cells and other immune cells and program them to execute new functions remains relatively primitive. Aside from CAR T cells for treatment of blood cancers, most engineered cell therapies are risky, potentially highly toxic, unreliable and often ineffective, especially those cell therapies that attempt to target solid cancers. We hypothesize that to fulfil the promise of engineered immune cell therapies, we must first transform cell engineering into a systematic and predictable process; one that uses reliable technology platforms and principles. Our center will focus on developing a set of sophisticated immune engineering platforms that address three major needs in next-generation cell therapies: 1) Smart recognition of cancer – develop antigen-pattern recognition circuits that direct immune cells to optimally recognize solid tumors and discriminate against normal tissue crossreaction, guided by computational bioinformatic analysis of gene expression patterns. 2) Overcoming the tumor microenvironment – develop multiple classes of cellular circuits that can overcome or locally remodel immune-suppressive tumor microenvironments to promote highly efficient therapeutic immune cell trafficking, proliferation, persistence, and tumor-killing activity 3) User-control and safety – to increase control over and safety of these powerful engineered cells, we will develop a suite of ways to communicate with and control the activity of engineered immune cells in vivo, including nano/microparticles and small molecules. To achieve these goals, we have assembled the UCSF Center for Synthetic Immunology, a tightly integrated interdisciplinary team that encompasses synthetic biologists, immunologists, bio-informaticists, control engineers, and materials scientists. The products of this center will include publicly available toolkits of parts and circuits for cell engineering, high-throughput platforms for rapid circuit assembly, new programmable nanomaterials for controlling immune cell behavior, searchable bioinformatic databases for optimization of tumor recognition, and computational frameworks for circuit design and for modeling/prototyping in vivo circuit function. These platforms will help to advance immune cell engineering to be far more reliable, predictable, effective and safe.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.cels.2020.08.002
发表时间: 2020-09-23
期刊: Cell systems
影响因子: 9.3
作者: [Dannenfelser R, Allen GM, VanderSluis B, Koegel AK, Levinson S, Stark SR, Yao V, Tadych A, Troyanskaya OG, Lim WA]
通讯作者: Lim WA
Golden age of immunoengineering.
免疫工程的黄金时代。
DOI: 10.1111/imr.13283
发表时间: 2023
期刊: Immunological reviews
影响因子: 8.7
作者: [Wong,WilsonW, Lim,WendellA]
通讯作者: Lim,WendellA
DOI: 10.1126/science.abb5607
发表时间: 2020-11-27
期刊: Science (New York, N.Y.)
影响因子: --
作者: [Li AW, Lim WA]
通讯作者: Lim WA
DOI: 10.1126/science.abc1855
发表时间: 2021-03-12
期刊: Science (New York, N.Y.)
影响因子: --
作者: [Hernandez-Lopez RA, Yu W, Cabral KA, Creasey OA, Lopez Pazmino MDP, Tonai Y, De Guzman A, Mäkelä A, Saksela K, Gartner ZJ, Lim WA]
通讯作者: Lim WA
Engineering synthetic immune cells with modular sentinel and therapeutic functions for T1D
Ameliorating off-target toxicities of CAR T cells by engineering NOT gates
Ameliorating off-target toxicities of CAR T cells by engineering NOT gates
Engineering synthetic immune cells with modular sentinel and therapeutic functions for T1D
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究